source
- Ipsen's Bylvay fails Phase 3 trial in children with biliary atresiaIpsen announced that its experimental therapy Bylvay did not meet its primary endpoint in a Phase 3 trial targeting biliary atresia in infants. Biliary atresia is a rare pediatric liver disorder i…
- FDA rejects Hengrui-Elevar liver cancer drug combo for third timeFor the third time in about two years, the FDA has cited manufacturing deficiencies in rejecting a drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics intended to treat th…Endpoints · 20d ago↗ source